COVID-19 Coagulopathy: From Pathogenesis to Treatment

Coronavirus disease 2019 (COVID-19) has emerged as a pandemic at the end of 2019 and continues to exert an unfavorable worldwide health impact on a large proportion of the population. A remarkable feature of COVID-19 is the precipitation of a hypercoagulable state, mainly in severe cases, leading to micro- and macrothrombosis, respiratory failure, and death. Despite the implementation of various therapeutic regimes, including anticoagulants, a large number of patients suffer from such serious complications. This review aims to describe the current knowledge on the pathophysiology of the coagulation mechanism in COVID-19. We describe the interplay between three important mediators of the disease and how this may lead to a hyperinflammatory and prothrombotic state that affects outcome, namely, the endothelium, the immune system, and the coagulation system. In line with the hypercoagulability state during COVID-19, we further review on the rare but severe vaccine-induced thrombotic thrombocytopenia. We also summarize and comment on available anticoagulant treatment options and include suggestions for some future treatment considerations for COVID-19 anticoagulation therapy.

Object Details

• Location: Deutsche Nationalbibliothek Frankfurt am Main
• Extent: Online-Ressource
• Language: Englisch

References and Relationships

• Bibliographic citation: COVID-19 Coagulopathy: From Pathogenesis to Treatment ; volume:145 ; number:3 ; year:2022 ; pages:282-296 ; extent:15 ; Acta haematologica ; 145, Heft 3 (2022), 282-296 (gesamt 15)

Contributors, Places and Time

• Creator: Alnima, Teba ; Mulder, Mark M.G. ; van Bussel, Bas C.T. ; ten Cate, Hugo

Further information

• DOI: 10.1159/000522498
• URN: urn:nbn:de:101:1-2022060901023270538266
• Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
• Last update: 15.08.2025, 7:22 AM CEST